EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy

Nisar Ul Khaliq iD, Juyeon Lee, Sangwoo Kim, Daekyung Sung iD, Hyungjun Kim iD

Pharmaceutics · 09.08.2023 · 15 (8) · 2102

DOI: 10.3390/pharmaceutics15082102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 09.08.2023. Verfasst von Nisar Ul Khaliq und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Bioscience, Kumoh National Institute of Technology, 61 Daehak-ro, Gumi 39177, Republic of Korea. Die Arbeit wurde bisher 180-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, This research was supported by Brain Pool program funded by the Ministry of Science and ICT through the National Research Foundation of Korea, Korea Institute of Ceramic Engineering and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pluronics are amphiphilic triblock copolymers composed of two hydrophilic poly (ethylene oxide) (PEO) chains linked via a central hydrophobic polypropylene oxide (PPO). Owing to their low molecular weight polymer and greater number of PEO segments, Pluronics induce micelle formation and gelation at critical micelle concentrations and temperatures. Pluronics F-68 and F-127 are the only United States (U.S.) FDA-approved classes of Pluronics and have been extensively used as materials for living bodies. Owing to the fascinating characteristics of Pluronics, many studies have suggested their role in biomedical applications, such as drug delivery systems, tissue regeneration scaffolders, and biosurfactants. As a result, various studies have been performed using Pluronics as a tool in nanomedicine and targeted delivery systems. This review sought to describe the delivery of therapeutic cargos using Pluronic F-68 and F-127-based cancer nanomedicines and their composites for combination therapy.

Schlagwörter

Stichwörter der Autor:innen

Pluronicscancer nanomedicinescombination therapygelationmicelle

Autor:innen und Institutionen

  • Department of Chemistry and Bioscience, Kumoh National Institute of Technology, 61 Daehak-ro, Gumi 39177, Republic of Korea.
  • Center for Bio-Healthcare Materials, Bio-Convergence Materials R&D Division, Korea Institute of Ceramic Engineering and Technology, 202 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju 28160, Republic of Korea.
  • Department of Chemical and Biomolecular Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.

ORCID-Profile: Nisar Ul Khaliq, Daekyung Sung, Hyungjun Kim

Förderung

  • National Research Foundation of Korea
  • This research was supported by Brain Pool program funded by the Ministry of Science and ICT through the National Research Foundation of Korea
  • Korea Institute of Ceramic Engineering and Technology
  • Ministry of Science and ICT

Zitieren

APA

Khaliq, N. U., Lee, J., Kim, S., Sung, D., & Kim, H. (2023). Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy. Pharmaceutics, 15(8), 2102. https://doi.org/10.3390/pharmaceutics15082102

Vancouver

Khaliq NU, Lee J, Kim S, Sung D, Kim H. Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy. Pharmaceutics. 2023;15(8):2102. doi:10.3390/pharmaceutics15082102

BibTeX
@article{Khaliq2023,
  author = {Khaliq, Nisar Ul and Lee, Juyeon and Kim, Sangwoo and Sung, Daekyung and Kim, Hyungjun},
  title = {Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {8},
  pages = {2102},
  doi = {10.3390/pharmaceutics15082102}
}
Kostenlos starten →